A pipeline analysis presented at the Alzheimer’s Association International Conference (AAIC 2017, 16–20 July, London, UK) has revealed that 27 Alzheimer’s drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may be on the market within the next 5 years. The analysis was reported by ResearchersAgainstAlzheimer’s (RA2), a network of UsAgainstAlzheimer’s.
Restricted Content / Members Only
You cannot view this content because It is available to members only. Please Login or Register to view this area.